190 related articles for article (PubMed ID: 28895089)
1. Bilateral Salpingo-Oophorectomy Versus GnRH Analogue in the Adjuvant Treatment of Premenopausal Breast Cancer Patients: Cost-Effectiveness Evaluation of Breast Cancer Outcome, Ovarian Cancer Prevention and Treatment.
Ferrandina G; Amadio G; Marcellusi A; Azzolini E; Puggina A; Pastorino R; Ricciardi W; Scambia G
Clin Drug Investig; 2017 Nov; 37(11):1093-1102. PubMed ID: 28895089
[TBL] [Abstract][Full Text] [Related]
2. Surgical ovarian suppression for adjuvant treatment in hormone receptor positive breast cancer in premenopausal patients.
Oseledchyk A; Gemignani ML; Zhou QC; Iasonos A; Elahjji R; Adamou Z; Feit N; Goldfarb SB; Long Roche K; Sonoda Y; Goldfrank DJ; Chi DS; Saban SS; Broach V; Abu-Rustum NR; Carter J; Leitao M; Zivanovic O
Int J Gynecol Cancer; 2021 Feb; 31(2):222-231. PubMed ID: 33273020
[TBL] [Abstract][Full Text] [Related]
3. Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors.
Suh KJ; Kim SH; Lee KH; Kim TY; Kim YJ; Han SW; Kang E; Kim EK; Kim K; No JH; Han W; Noh DY; Lee M; Kim HS; Im SA; Kim JH
Cancer Res Treat; 2017 Oct; 49(4):1153-1163. PubMed ID: 28253566
[TBL] [Abstract][Full Text] [Related]
4. Laparoscopic salpingo-oophorectomy for ovarian ablation in women with hormone-sensitive breast cancer.
Haldar K; Giamougiannis P; Wilson C; Crawford R
Int J Gynaecol Obstet; 2011 Jun; 113(3):222-4. PubMed ID: 21457974
[TBL] [Abstract][Full Text] [Related]
5. Specifying the ovarian cancer risk threshold of 'premenopausal risk-reducing salpingo-oophorectomy' for ovarian cancer prevention: a cost-effectiveness analysis.
Manchanda R; Legood R; Antoniou AC; Gordeev VS; Menon U
J Med Genet; 2016 Sep; 53(9):591-9. PubMed ID: 27354448
[TBL] [Abstract][Full Text] [Related]
6. Concurrent risk-reduction surgery in patients with increased lifetime risk for breast and ovarian cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database.
Elmi M; Azin A; Elnahas A; McCready DR; Cil TD
Breast Cancer Res Treat; 2018 Aug; 171(1):217-223. PubMed ID: 29761322
[TBL] [Abstract][Full Text] [Related]
7. Salpingo-oophorectomy or surveillance for ovarian endometrioma in asymptomatic premenopausal women: a cost-effectiveness analysis.
Orlando MS; Cadish LA; Shepherd JP; Falcone T; Chang OH; Kho RM
Am J Obstet Gynecol; 2022 Aug; 227(2):311.e1-311.e7. PubMed ID: 35490792
[TBL] [Abstract][Full Text] [Related]
8. Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
Müller D; Danner M; Schmutzler R; Engel C; Wassermann K; Stollenwerk B; Stock S; Rhiem K
Eur J Health Econ; 2019 Jul; 20(5):739-750. PubMed ID: 30790097
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.
Müller D; Danner M; Rhiem K; Stollenwerk B; Engel C; Rasche L; Borsi L; Schmutzler R; Stock S
Eur J Health Econ; 2018 Apr; 19(3):341-353. PubMed ID: 28382503
[TBL] [Abstract][Full Text] [Related]
10. Long-term consequences of ovarian ablation for premenopausal breast cancer.
Kwon JS; Pansegrau G; Nourmoussavi M; Hammond G; Carey MS
Breast Cancer Res Treat; 2016 Jun; 157(3):565-73. PubMed ID: 27236562
[TBL] [Abstract][Full Text] [Related]
11. Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women.
Manchanda R; Legood R; Pearce L; Menon U
Gynecol Oncol; 2015 Dec; 139(3):487-94. PubMed ID: 26436478
[TBL] [Abstract][Full Text] [Related]
12. Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations.
Hallsson LR; Sroczynski G; Engel J; Siebert U
BMC Cancer; 2023 Jun; 23(1):590. PubMed ID: 37365514
[TBL] [Abstract][Full Text] [Related]
13. BRCA carriers after risk-reducing bilateral salpingo-oophorectomy: menopausal hormone therapy knowledge gaps, and the impact of physicians' recommendations.
Armon S; Miron-Shatz T; Mor P; Tomer A; Levy-Lahad E; Michaelson-Cohen R; Srebnik N
Climacteric; 2023 Apr; 26(2):154-160. PubMed ID: 36866779
[TBL] [Abstract][Full Text] [Related]
14. Comparison of outcomes in patients with luminal type breast cancer treated with a gonadotropin-releasing hormone analog or bilateral salpingo-oophorectomy: A cohort retrospective study.
Andriyanto DR; Prihantono ; Syamsu SA; Kusuma MI; Hendarto J; Indra ; Smaradania N; Sampepajung E; Mappiwali A; Faruk M
Ann Med Surg (Lond); 2022 May; 77():103614. PubMed ID: 35637977
[TBL] [Abstract][Full Text] [Related]
15. [The use of GnRH analogues in early and advanced breast carcinomas].
Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinoma.
Stahl JM; Damast S; Bledsoe TJ; An Y; Verma V; Yu JB; Young MR; Lester-Coll NH
Brachytherapy; 2018; 17(2):399-406. PubMed ID: 29275078
[TBL] [Abstract][Full Text] [Related]
17. Laparoscopic oophorectomy either with or without hysterectomy for early breast cancer.
Kucera E; Holub Z; Svobodova G
Eur J Gynaecol Oncol; 2007; 28(4):294-6. PubMed ID: 17713096
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic laparoscopic ovarian ablation for premenopausal breast cancer: medical and economic efficacy.
Kwon AH; Yamada O; Uetsuji S; Matsui Y; Kamiyama Y
Surg Laparosc Endosc; 1997 Jun; 7(3):223-7. PubMed ID: 9194283
[TBL] [Abstract][Full Text] [Related]
19. Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer.
Simoes Correa-Galendi J; Del Pilar Estevez Diz M; Stock S; Müller D
Appl Health Econ Health Policy; 2021 Jan; 19(1):97-109. PubMed ID: 32537695
[TBL] [Abstract][Full Text] [Related]
20. Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy.
Kim HJ; Lee MH; Lee JE; Park S; Lee ES; Kang YJ; Shin HN; Kim SI; Lee JH; Im SA; Ahn SH; Lee KS; Sohn J; Kim S; Nam SJ; Han W
Clin Breast Cancer; 2018 Oct; 18(5):e1165-e1172. PubMed ID: 29843988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
